Drugs for Bladder Neck Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 24)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Alfuzosin |
Approved, Investigational |
Phase 4 |
|
81403-80-7 |
2092 |
Synonyms:
(±)-N-[3-[(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)METHYLAMINO]PROPYL]TETRAHYDRO-2-FURAMIDE
Alfetim
Alfusosine
Alfusozine
ALFUZOSIN
Alfuzosin hydrochloride
Alfuzosina
Alfuzosine
Alfuzosinum
Alphuzosine
|
Benestan
N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide
N-[3-[(4-AMINO-6,7-DIMETHOXY-QUINAZOLIN-2-YL)- METHYL-AMINO]PROPYL] TETRAHYDROFURAN- 2-CARBOXAMIDE
SL-7749910
SL-77499-10
SL-77499-10|SL-7749910|Uroxatral®
Urion
UroXatral
Xatral
|
|
2 |
|
Tamsulosin |
Approved, Investigational |
Phase 4 |
|
106133-20-4 |
129211 |
Synonyms:
(−)-tamsulosin
(-)-Tamsulosin
(-)-YM617
(-)-YM617|Flomax®|LY-253351|Omnic®|tamsulosin hydrochloride
(R)-(−)-tamsulosin
(R)-(-)-Tamsulosin
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulphonamide
5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulphonamide
Flomax
Harnal
HGP-0412
HIP1402
|
HIP-1402
LY-253351
OMNIC
Pradif
Tamsolusin
Tamsulon
TAMSULOSIN
Tamsulosin hydrochloride
Tamsulosina
Tamsulosina [INN-Spanish]
Tamsulosine
Tamsulosine [INN-French]
Tamsulosinum
Tamsulosinum [INN-Latin]
YM-617
|
|
3 |
|
Fesoterodine |
Approved |
Phase 4 |
|
286930-03-8, 286930-02-7 |
6918558 |
Synonyms:
FESO
Fesoterodina
Fesoterodine
Fesoterodine fumarate
|
|
|
4 |
|
Doxazosin |
Approved |
Phase 4 |
|
74191-85-8 |
3157 |
Synonyms:
1 (4-amino-6,7-Dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine
1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
Alfamedin
Aliud brand OF doxazosin mesylate
Almirall brand OF doxazosin mesylate
Alpharma brand OF doxazosin mesylate
Alter brand OF doxazosin mesylate
apo Doxazosin
apo-Doxazosin
Apogepha brand OF doxazosin mesylate
Apotex brand OF doxazosin mesylate
AstraZeneca brand OF doxazosin mesylate
Azupharma brand OF doxazosin mesylate
Betapharm brand OF doxazosin mesylate
C02CA04
Cantabria brand OF doxazosin mesylate
Cardular
Cardura
Cardura XL
Cardura®|UK-3327427
Carduran
Carduran neo
Ciclum brand OF doxazosin mesylate
Cinfa brand OF doxazosin mesylate
combino Brand OF doxazosin mesylate
CT Arzneimittel brand OF doxazosin mesylate
CT, Doxazosin von
CT-Arzneimittel brand OF doxazosin mesylate
Diblocin
Doxa puren
Doxacor
Doxagamma
Doxamax
Doxa-puren
Doxatensa
DoxaUro
Doxazomerck
Doxazosin
Doxazosin al
Doxazosin apogepha
Doxazosin azu
Doxazosin beta
Doxazosin findusfit
Doxazosin heumann
Doxazosin klast
Doxazosin mesilate
Doxazosin mesylate
Doxazosin monohydrochloride
Doxazosin ratiopharm
Doxazosin stada
Doxazosin von CT
Doxazosin wolff
Doxazosina
|
Doxazosina alter
Doxazosina cinfa
Doxazosina combino pharm
Doxazosina geminis
Doxazosina normon
Doxazosina pharmagenus
Doxazosina ratiopharm
Doxazosina ur
Doxazosine
Doxazosin-ratiopharm
Doxazosinum
Doxazosin-wolff
Esparma brand OF doxazosin mesylate
FindusFit brand OF doxazosin mesylate
Geminis brand OF doxazosin mesylate
Gen doxazosin
Gen-doxazosin
Genpharm brand OF doxazosin mesylate
Heumann brand OF doxazosin mesylate
Hexal brand OF doxazosin mesylate
Juta brand OF doxazosin mesylate
Jutalar
Kade brand OF doxazosin mesylate
Linden brand OF doxazosin mesylate
Merck dura brand OF doxazosin mesylate
Mesylate, doxazosin
Monohydrochloride, doxazosin
MTW Brand OF doxazosin mesylate
MTW Doxazosin
MTW-Doxazosin
neo, Carduran
Normon brand OF doxazosin mesylate
novo Doxazosin
novo-Doxazosin
Novopharm brand OF doxazosin mesylate
Pfizer brand OF doxazosin mesylate
Pharmagenus brand OF doxazosin mesylate
Progandol neo
Q Pharm brand OF doxazosin mesylate
Q-Pharm brand OF doxazosin mesylate
ratio Doxazosin
ratio-Doxazosin
Ratiopharm brand OF doxazosin mesylate
Ratiopharm, doxazosina
Solvay brand OF doxazosin mesylate
Stadapharm brand OF doxazosin
TAD brand OF doxazosin mesylate
UK-33274
UK-3327427
Uriduct
Von CT, doxazosin
Wolff brand OF doxazosin mesylate
Wörwag brand OF doxazosin mesylate
Zoxan
|
|
5 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
6 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
7 |
|
Adrenergic alpha-Antagonists |
|
Phase 4 |
|
|
|
8 |
|
Adrenergic alpha-1 Receptor Antagonists |
|
Phase 4 |
|
|
|
9 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
10 |
|
Muscarinic Antagonists |
|
Phase 4 |
|
|
|
11 |
|
Cholinergic Antagonists |
|
Phase 4 |
|
|
|
12 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
13 |
|
Tolterodine Tartrate |
|
Phase 4 |
|
124937-52-6 |
|
Synonyms:
DETROL
DETROL LA
PNU-200583E
|
TOLTERODINE L-TARTRATE
TOLTERODINE TARTRATE
|
|
14 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
15 |
|
Mirabegron |
Approved |
Phase 2 |
|
223673-61-8 |
18319735 9865528 |
Synonyms:
BETMIGA
Betmiga®|Myrbetriq®|YM-178
MIRABEGRON
|
|
|
16 |
|
Solifenacin Succinate |
|
Phase 2 |
|
242478-38-2 |
216457 |
Synonyms:
SOLIFENACIN SUCCINATE
VESICARE
|
|
|
17 |
|
Adrenergic beta-Agonists |
|
Phase 2 |
|
|
|
18 |
|
Adrenergic beta-3 Receptor Agonists |
|
Phase 2 |
|
|
|
19 |
|
Adrenergic Agonists |
|
Phase 2 |
|
|
|
20 |
|
Ceftriaxone |
Approved |
|
|
73384-59-5 |
5479530 |
Synonyms:
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulphanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulphanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Anhydrous ceftriaxone sodium
Benaxona
Biotrakson
Boehringer mannheim brand OF ceftriaxone sodium
C18H18N8O7S3
Cefatriaxone
Cefaxona
Ceftrex
Ceftriaxon
Ceftriaxon curamed
Ceftriaxon hexal
Ceftriaxona
Ceftriaxona [INN-Spanish]
Ceftriaxona andreu
Ceftriaxona LDP torlan
CEFTRIAXONE
Ceftriaxone irex
Ceftriaxone sodium
Ceftriaxone sodium, anhydrous
Ceftriaxone, disodium salt
Ceftriaxone, disodium salt, hemiheptahydrate
Ceftriaxonum
|
Ceftriaxonum [INN-Latin]
Ceftriazone
Columbia brand OF ceftriaxone
CTRX
Curamed brand OF ceftriaxone sodium
FIDATO
Fustery brand OF ceftriaxone sodium
Galen brand OF ceftriaxone sodium
Hexal brand OF ceftriaxone sodium
Hoffman la roche brand OF ceftriaxone sodium
Hoffman-la roche brand OF ceftriaxone sodium
Inibsa brand OF ceftriaxone sodium
Irex brand OF ceftriaxone
Lendacin
Longacef
Longaceph
Pisa brand OF ceftriaxone sodium
Rocefalin
Rocefin
Rocephin
Rocephine
Roche brand OF ceftriaxone sodium
Sodium, ceftriaxone
Syntex brand OF ceftriaxone sodium
Tacex
Terbac
|
|
21 |
|
Lidocaine |
Approved, Vet_approved |
|
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
22 |
|
Anesthetics |
|
|
|
|
|
23 |
|
Anti-Bacterial Agents |
|
|
|
|
|
24 |
|
Antibiotics, Antitubercular |
|
|
|
|
|
Interventional clinical trials:
(show all 34)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Long Term Effects of Alfuzosin(Xatral XL) in LUTS/BPH Patients: Evaluation of Voiding and Storage Function According to Bladder Outlet Obstruction Grade and Bladder Contractility |
Completed |
NCT00696761 |
Phase 4 |
Alfuzosin |
2 |
A Randomized, Double Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER Plus Tamsulosin) Study To Evaluate The Clinical Efficacy And Safety Of Tolterodine ER 4 mg In Men Who Have Frequency and Urgency, With Or Without Urinary Urge Incontinence, With Or Without Bladder Outlet Obstruction |
Completed |
NCT00147654 |
Phase 4 |
Tolterodine ER 4 mg QD;Tamsulosin 0.4 mg QD |
3 |
An Open Label Study to Measure the Efficacy of Fesoterodine (Toviaz) on Continued Detrusor Overactivity in Patients That Have Undergone Treatment for Bladder Outlet Obstruction |
Completed |
NCT00605319 |
Phase 4 |
Toviaz (Fesoterodine) |
4 |
Antimuscarinics as the First-line Treatment for Male With International Prostate Symptom Score (IPSS) Voiding-to-storage Subscore Rati (IPSS-V/S)≤1-- A Prospective Randomized Study Comparing With α-blockers |
Completed |
NCT01661621 |
Phase 4 |
Detrusitol 4 mg QD;Doxazosin 4 mg QD |
5 |
The Long Term Effects of Alfuzosin (Xatral XL) in LUTS/BPH Patients: Evaluation of Symptom-specific Goal Achievement According to Symptom Improvement, Bladder Outlet Obstruction Grade and Bladder Contractility |
Completed |
NCT00836823 |
Phase 4 |
Alfuzosin |
6 |
Anatomical Endoscopic Enucleation of the Prostate for Treatment of Bladder Outlet Obstruction in Patients With Low-risk Prostate Cancer on Surveillance Protocol, Prospective Assessment of Functional and Oncological Outcome |
Active, not recruiting |
NCT05631080 |
Phase 4 |
|
7 |
Uroflowmetry Parameter (Delta Q Value) as a Noninvasive Tool to Discriminate Detrusor Underactivity From Bladder Outlet Obstruction |
Completed |
NCT05359484 |
Phase 2, Phase 3 |
|
8 |
Effectiveness and Safety of Local Endoscopically-assisted Administration of Autologous Adipose-derived Regenerative Cells for Reduction of Risk of Postoperative Bladder Neck Contracture in Male Patients |
Unknown status |
NCT02869061 |
Phase 1, Phase 2 |
|
9 |
A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate With 0.4 mg Tamsulosin Hydrochloride OCAS (TOCAS) Using Urodynamics in Male Subjects With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) |
Completed |
NCT00507455 |
Phase 2 |
solifenacin succinate;tamsulosin hydrochloride;Placebo to solifenacin;Placebo to tamsulosin |
10 |
A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study to Evaluate the Urodynamics and Safety of YM178 in Male Subjects With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) |
Completed |
NCT00410514 |
Phase 2 |
Mirabegron;Placebo |
11 |
The Role Of Prophylactic Urethral Stenting With Memokath® 028SW in Patients Undergoing Prostate 125I Seed Implants For Prostate Carcinoma: A Phase I/II Study |
Completed |
NCT00252941 |
Phase 1, Phase 2 |
|
12 |
Diagnosis of Bladder Outlet Obstruction Using Dynamic Urine Vibration "Holter" in Comparison to Pressure Flow Study |
Unknown status |
NCT01388348 |
|
|
13 |
Bipolar Transurethral Enucleation (BipolEP) vs Bipolar Transurethral Resection of the Prostate: A Prospective Interventional Multi-center Randomized Controlled Trial |
Unknown status |
NCT03503721 |
|
|
14 |
Short- and Medium-term Safety/Effectiveness Analysis of Low Energy Holmium Laser Enucleation of the Prostate (HoLEP) |
Unknown status |
NCT04514718 |
|
|
15 |
Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity |
Unknown status |
NCT03486639 |
|
|
16 |
Bladder and Prostate Sonomorphology as a Useful Tool for Detecting Bladder Outlet Obstruction in Patients With Symptomatic Benign Prostatic Hyperplasia |
Unknown status |
NCT04352257 |
|
|
17 |
Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM) for Diagnosis and Management of Bladder Outlet Obstruction in Men |
Unknown status |
NCT02193451 |
|
|
18 |
Investigating the Role of microRNAs in the Regulation of Gene Expression and Organ Remodeling During Lower Urinary Tract Dysfunction, Including Bladder Pain Syndrome/Interstitial Cystitis (BPS), and Overactive Bladder Syndrome (OAB) |
Completed |
NCT01482676 |
|
|
19 |
One-arm Feasibility and Prospective Pivotal Study to Assess the Safety and Efficacy of MediTate Temporary Implantable Nitinol Device (TIND) in Subjects Presenting Bladder Outlet Obstruction Secondary to BPH |
Completed |
NCT01436877 |
|
|
20 |
Urodynamically Age-specific Prevalence of Detrusor Underactivity and Bladder Outlet Obstruction in Female Voiding Dysfunction Without Cystocele |
Completed |
NCT04184752 |
|
|
21 |
An Open Prospective Multicenter Study Comparing the Urine Flow Measurements of Standard Clinic Flow Measurements vs Comercially Available Portable Digital Flow Meters and a Disposable Flow Meter in a Crossover and Randomized Order on Male BPH Subjects |
Completed |
NCT00710749 |
|
|
22 |
Comparison Between Invasive Pressure Flow Study and Non-invasive Penile Cuff Test |
Completed |
NCT02031653 |
|
|
23 |
Prevalence of Detrusor Underactivity and Bladder Outlet Obstruction in Women With Cystocele and Changes of Voiding Function After Cystocele |
Completed |
NCT04184128 |
|
|
24 |
Prevalence Rates of Bladder Outlet Obstruction and Detrusor Underactivity and Their Clinical and Urodynamic Findings in Women With ≥Stage II Cystocele |
Completed |
NCT03613324 |
|
|
25 |
Prevalence of Detrusor Underactivity and Bladder Outlet Obstruction in Women With and Without Symptoms of Voiding Dysfunction |
Completed |
NCT04981080 |
|
|
26 |
Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction (LUTO): A Prospective Trial |
Recruiting |
NCT03281798 |
|
|
27 |
Concomitant Renal and Urinary Bladder Allograft Transplantation |
Recruiting |
NCT04626167 |
Early Phase 1 |
|
28 |
Prostatic Artery Embolization (PAE) in Patients With Advanced Prostate Cancer: A Pilot Study. |
Recruiting |
NCT03457805 |
|
|
29 |
Prospective, Open-Label, Non-Comparative, Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients. |
Recruiting |
NCT03912558 |
|
|
30 |
Prospective, Open-Label, Non-Comparative, Study to Assess the Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients Who Completed 12 Months of Follow-Up Post Implantation (Continuation Study for Study BM-011-IL) |
Recruiting |
NCT05330520 |
|
|
31 |
Soractelite(Tm) Transperineal Laser Ablation for Benign Prostatic Hyperplasia With Bladder Outlet Obstruction |
Recruiting |
NCT04760483 |
|
|
32 |
Effect of Concomitant Bladder Neck Incision and Urethral Valve Ablation on Surgical Re-intervention Rate for Patients With Posterior Urethral Valve : A Randomized Controlled Trial |
Active, not recruiting |
NCT05087537 |
|
|
33 |
A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ Air for Men Intermittent Catheter With FeelClean™ Technology |
Not yet recruiting |
NCT05470751 |
|
|
34 |
Bladder Outlet Obstruction Observation Using Dynamic Urine Vibration "Holter" With Correlation to Pressure Flow Study and Uroflowmetry. |
Suspended |
NCT01779349 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Phenoxybenzamine
|
Phenoxybenzamine Hydrochloride
|
|